QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: mol.105.014191v1 68/5/1311    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Putral, L. N. Articles by McMillan, N. A. J. Search for Related Content PubMed PubMed Citation Articles by Putral, L. N. Articles by McMillan, N. A. J.

RNA Interference against Human Papillomavirus Oncogenes in Cervical Cancer Cells Results in Increased Sensitivity to Cisplatin

Cancer Biology Program (L.N.P., M.J.B., W.G., N.A.S., B.G.G., N.A.J.M.) and Immunology Program (G.R.L.), Centre for Immunology and Cancer Research, Princess Alexandra Hospital, University of Queensland, Brisbane, Australia

Targeted inhibition of oncogenes in tumor cells is a rational approach toward the development of cancer therapies based on RNA interference (RNAi). Tumors caused by human papillomavirus (HPV) infection are an ideal model system for RNAi-based cancer therapies because the oncogenes that cause cervical cancer, E6 and E7, are expressed only in cancerous cells. We investigated whether targeting HPV E6 and E7 oncogenes yields cancer cells more sensitive to chemotherapy by cisplatin, the chemotherapeutic agent currently used for the treatment of advanced cervical cancer. We have designed siRNAs directed against the HPV E6 oncogene that simultaneously targets both E6 and E7, which results in an 80% reduction in E7 protein and reactivation of the p53 pathway. The loss of E6 and E7 resulted in a reduction in cellular viability concurrent with the induction of cellular senescence. Interference was specific in that no effect on HPV-negative cells was observed. We demonstrate that RNAi against E6 and E7 oncogenes enhances the chemotherapeutic effect of cisplatin in HeLa cells. The IC₅₀ for HeLa cells treated with cisplatin was 9.4 µM, but after the addition of a lentivirus-delivered shRNA against E6, the IC₅₀ was reduced almost 4-fold to 2.4 µM. We also observed a decrease in E7 expression with a concurrent increase in p53 protein levels upon cotreatment with shRNA and cisplatin over that seen with individual treatment alone. Our results provide strong evidence that loss of E6 and E7 results in increased sensitivity to cisplatin, probably because of increased p53 levels.

Address correspondence to: Nigel A. J. McMillan, CICR, R-Wing, Princess Alexandra Hospital, Ipswich Rd, Brisbane, QLD 4102, Australia. E-mail: n.mcmillan{at}uq.edu.au

This article has been cited by other articles:

				G. A. Darnell, W. A. Schroder, T. M. Antalis, E. Lambley, L. Major, J. Gardner, G. Birrell, A. Cid-Arregui, and A. Suhrbier Human Papillomavirus E7 Requires the Protease Calpain to Degrade the Retinoblastoma Protein J. Biol. Chem., December 28, 2007; 282(52): 37492 - 37500. [Abstract] [Full Text] [PDF]

				V. K. Jamburuthugoda, P. Chugh, and B. Kim Modification of Human Immunodeficiency Virus Type 1 Reverse Transcriptase to Target Cells with Elevated Cellular dNTP Concentrations J. Biol. Chem., May 12, 2006; 281(19): 13388 - 13395. [Abstract] [Full Text] [PDF]